Search

Author/Creator Eckert, Karl

1. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. (5th June 2018)

Authors:
Jones, Jeffrey; Mato, Anthony; Coutre, Steven; Byrd, John C.; Furman, Richard R.; Hillmen, Peter; Osterborg, Anders; Tam, Constantine; Stilgenbauer, Stephan; Wierda, William G.; Heerema, Nyla A.; Eckert, Karl; Clow, Fong; Zhou, Cathy; Chu, Alvina D.; James, Danelle F.; O'Brien, Susan M.
Journal:
British journal of haematology
Issue:
Volume 182:Number 4(2018)
Page Start:
504
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma. (16th March 2020)

Authors:
Fowler, Nathan H.; Nastoupil, Loretta; De Vos, Sven; Knapp, Mark; Flinn, Ian W.; Chen, Robert; Advani, Ranjana H.; Bhatia, Sumeet; Martin, Peter; Mena, Raul; Davis, Richard Eric; Neelapu, Sattva S.; Eckert, Karl; Ping, Jerry; Co, Melannie; Beaupre, Darrin M.; Neuenburg, Jutta K.; Palomba, M. Lia
Journal:
British journal of haematology
Issue:
Volume 189:Number 4(2020)
Page Start:
650
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study. (February 2023)

Authors:
Ramchandren, Radhakrishnan; Johnson, Peter; Ghosh, Nilanjan; Ruan, Jia; Ardeshna, Kirit M.; Johnson, Roderick; Verhoef, Gregor; Cunningham, David; de Vos, Sven; Kassam, Shireen; Fayad, Luis; Radford, John; Bailly, Sarah; Offner, Fritz; Morgan, David; Munoz, Javier; Ping, Jerry; Szafer-Glusman, Ed...
Journal:
EClinicalMedicine
Issue:
Volume 56(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗